Not positive news! They are basically doing another trial and they will need more money to run trial. Also how do you know that maybe they are not getting the desired or long lasting response and they want to see if more treatments will give a better result!
29/30 patients enrolled and patient receives treatment every 12 weeks and interm analysis at 180 days means the last patient, which isn't enrolled yet won't give data till September. That right?
Legacy shareholders bet on the track record of heckman and #$%$ Heckman made a huge bad bet on china water and over paid for oil/gas acquisitions as the sector peaked and johnsrud took control as majority shareholder.
At this point the company is transforming from a failed growth company to a turn around play. Johnsrud spent last 12 months shoring up the company and stabilizing balance sheet and he is and will put his people in place. He will spend the next 4 quarters right sizing the business and lay down debt and show profits in a few quarters. Get the stock price into upper 20s and raise more cash at reasonable rates or through offering and put debt at industry levels and then look to grow company again. It's not rocket science but it will take time to fix company. There is significant value but it will take 18 months to repair company and credibility. When they report two or more quarters of significant improvement, short interest will drop and share price will recover and their will be a new story in place!
Can you share thoughts on Mack? With the backing up of 398 trial waiting for results, one would assume longer life expectancy and positive results? 121 I'm confused on and afraid SNY will bail on the program?
200m shelf just filed thoughts on that?
Hard to conduct a trial without a supply of the units???
So what pr do you think comes next? Maybe glucagon trial?
Wouldn't you start to build inventory prior to approval?
Wouldn't you line up distributors before approval?
I agree most people don't get it! Stock compensation is bulk of pay package and gives incentives not to jump ship and pay for performance
My guess is they are issuing shelf now so if 398 is positive and price moves up, they will do secondary to raise more cash to conduct multiple trials or as leverage against a partner to go it alone.
Talks with Sanofi are not going as well as hoped and Mack might run separate trials for 121.
At least I have the acument and intelligence to know when I made a bad bet and get out of it! Enjoy! PS market was up 30% last year and biotechs were up 50%
read the sec filing they reserved 270 million shares. Less than $270,000. They also bought a water company for oil and gas. Note they didn't list all the financials of the company. You have to use common sense. This is a shell company. Next step is they will change the name of the company, to "reflect the new strategy of the company"
I completely understand your frustrated response! I will be more than happy to give the 3 of you a pat on the back. Please give me a guide of when to check in? Summer? Fall?
My point was you guys have been losing money in here for years as I was and your losing the opportunity cost as well.
I'm a little confused as well. With 398 looking to report strong results and on the cc, they said they would move as fast as possible into production mode and partnering already on going. Doesn't Mack jump to 7/8$ on a positive 398 readout and potentially $10 plus as a partner would follow potentially in the following 60 days?